Innovating Works

DaV

Desconocido
COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections DA VOLTERRA SAS participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado
COMBACTE-NET: Combatting Bacterial Resistance in Europe DA VOLTERRA SAS participó en un FP6: The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified...
2013-01-01 - 2021-02-28 | Financiado
ENDETECH: ENzymatic DEcontamination TECHnology DA VOLTERRA SAS tramitó un FP7: Human activities are associated with increasing amounts of waste that ultimately find their ways into European waters and have negative cons...
Financiado
EVOTAR: Evolution and Transfer of Antibiotic Resistance DA VOLTERRA SAS participó en un FP7: Antibiotics are essential therapeutics in the treatment of bacterial infections. However, the indiscriminate use of antibiotics has led to t...
Financiado
COMBACTE-NET: Combatting Bacterial Resistance in Europe DA VOLTERRA SAS participó en un FP7: The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified...
Financiado
R-GNOSIS: Resistance in Gram Negative Organisms Studying Intervention Strategies DA VOLTERRA SAS participó en un FP7: Antibiotics are a mainstay of public health, but their use has increased exponentially leading to the emergence of antibiotic resistance. Th...
Financiado
TRAIN-ASAP: Training and Research AImed at Novel Antibacterial Solutions in Animals and People DA VOLTERRA SAS participó en un FP7: TRAIN-ASAP addresses a very urgent public health issue. The lack of effective antibacterial drugs against resistant bacteria poses a serious...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.